Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Friedreich's Ataxia
Biotech
Lexeo links gene therapy to improvements in rare heart disease
Lexeo Therapeutics ran into problems when testing the effect of a Friedreich ataxia gene therapy on fitness and was left with a gap in its evidence.
Nick Paul Taylor
Jul 15, 2024 9:46am
FDA picks Denali, Neurogene and more for rare disease program
Jun 4, 2024 2:51pm
Larimar's Friedreich's ataxia program free at last from FDA hold
May 21, 2024 9:55am
After pair of failures, PTC finds path for Friedreich ataxia med
Mar 1, 2024 9:20am
FDA demands data on 2 PTC candidates, delaying filing
Oct 27, 2023 7:30am
Design rethinks lead drug, causing delay and steep stock drop
Aug 15, 2023 8:50am